Platinum-Based Doublets As the Cornerstone of First Line Treatment
Dr. Benjamin Levy, Mount Sinai Health Systems, discusses platinum-based chemotherapy as the standard of care for advanced NSCLC patients without targetable genetic mutations.
Dr. Benjamin Levy, Mount Sinai Health Systems, discusses platinum-based chemotherapy as the standard of care for advanced NSCLC patients without targetable genetic mutations.
Transcript
I think there are several goals when treating a patient with advanced non-small cell lung cancer. For one I think we want to extend life, two is I think we want to palliate symptoms, and three is I think we want to improve quality of life. So all three of those goals are achievable, I think, with the therapies that we have right now.
Dr. Jared Weiss, UNC Lineberger Comprehensive Cancer Center, evaluates a variety of particular systemic treatment agents for possible use in elderly patients.
WHAT: Acquired Resistance in Lung Cancer Patient Forum
WHEN: Saturday, Oct. 3, 2015
WHERE: Marriott Waterfront San Francisco, 1800 Old Bayshore Hwy, Burlingame, CA 94010
WHO: ALK, ROS1 & EGFR lung cancer patients and their caregivers
REGISTER HERE
Liquid biopsies (also called serum testing) is a practice already approved in Europe for EGFR lung cancer patients. Drawing blood to test for acquired resistance is easier and quicker than needle biopsies. How long until it is standard practice in the US?
[powerpress]
A study released at ASCO 2015 showed that the BRAF V600E mutation had a high response rate to combination therapy Tafinlar (dabrafenib) plus Mekinist (trametinib), which led the doctors to agree that BRAF testing in lung cancer should become commonplace.
[powerpress]
A trial studying Cometriq (cabozantinib) for RET rearrangements showed a promising response rate, which led the doctors to discuss if they think RET is going to be the next actionable target in lung cancer.
Please feel free to offer comments and raise questions in our Discussion Forums.
A trial comparing Tarceva (erlotinib) to Cometriq (cabozantinib) showed modest benefit for EGFR wild type patients, but the challenging side effect profile should lead us to question if we can identify only patients most likely to benefit from Cometriq.
[powerpress]
Dr. Thomas John is a thoracic oncologist at the Olivia Newton-John Cancer and Wellness Centre in Australia.
The American Society of Clinical Oncology's (ASCO) Annual Meeting brings together 30,000 oncology professionals from around the world. Educational sessions feature world-renowned faculty discussing state-of-the-art treatment modalities, new therapies, and ongoing controversies in the field. The meeting will take place May 29 - June 2, 2015.
Thoracic oncologist Dr. Ben Levy highlights what he believes was the biggest news for lung cancer patients in 2014 as well as his take on exciting clinical trials taking place in lung cancer in 2015.
Download a transcript of the video
[powerpress]
Copyright © 2021 Global Resource for Advancing Cancer Education
Site by Freelock